Galena Biopharma to Report Second Quarter 2016 Fin
Post# of 23071
Posted On: 07/26/2016 8:22:09 AM
Galena Biopharma to Report Second Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, August 9, 2016
1 hour 16 minutes ago - DJNF
Galena Biopharma to Report Second Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, August 9, 2016
SAN RAMON, Calif., July 26, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that the Company will report its second quarter 2016 financial results and provide a corporate update on Tuesday, August 9, 2016 after the close of the financial markets. The company will host a conference call following the announcement at 2:00 p.m. P.T./5:00 pm E.T. to discuss the financial and business results.
The live webcast will include slides that can be accessed on the Company's website under the Investors section/Events and Presentations: http://investors.galenabiopharma.com/events.cfm. The conference call can be accessed by dialing (844) 825-4413 toll-free in the U.S., or (973) 638-3403 for participants outside the U.S. The Conference ID number is: 51743330. The archived webcast replay will be available on the Company's website for one year.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena's development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The company's pipeline consists of multiple mid-to-late-stage clinical assets, including novel cancer immunotherapy programs with NeuVax(TM) (nelipepimut-S) and GALE-301/GALE-302, and one hematology program, GALE-401. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(503) 405-8258
rbernarda@galenabiopharma.com
(MORE TO FOLLOW) Dow Jones Newswires
July 26, 2016 07:05 ET (11:05 GMT)
1 hour 16 minutes ago - DJNF
Galena Biopharma to Report Second Quarter 2016 Financial Results and Provide a Corporate Update on Tuesday, August 9, 2016
SAN RAMON, Calif., July 26, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that the Company will report its second quarter 2016 financial results and provide a corporate update on Tuesday, August 9, 2016 after the close of the financial markets. The company will host a conference call following the announcement at 2:00 p.m. P.T./5:00 pm E.T. to discuss the financial and business results.
The live webcast will include slides that can be accessed on the Company's website under the Investors section/Events and Presentations: http://investors.galenabiopharma.com/events.cfm. The conference call can be accessed by dialing (844) 825-4413 toll-free in the U.S., or (973) 638-3403 for participants outside the U.S. The Conference ID number is: 51743330. The archived webcast replay will be available on the Company's website for one year.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena's development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The company's pipeline consists of multiple mid-to-late-stage clinical assets, including novel cancer immunotherapy programs with NeuVax(TM) (nelipepimut-S) and GALE-301/GALE-302, and one hematology program, GALE-401. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(503) 405-8258
rbernarda@galenabiopharma.com
(MORE TO FOLLOW) Dow Jones Newswires
July 26, 2016 07:05 ET (11:05 GMT)
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'